Genevant and Arbutus initiate patent lawsuit against Moderna

4 March 2025

Roivant Sciences (Nasdaq: ROIV) portfolio company Genevant Sciences and Canada’s Arbutus Biopharma (Nasdaq: ABUS) yesterday filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna (Nasdaq: MRNA), and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.

Genevant and Arbutus said they are seeking monetary relief and injunctions against Moderna’s Covid-19 jab Spikevax and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA. Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the USA and Europe indicating that the samples contain LNPs falling under the protective scope of the claims of their lipid composition patents.

The legal actions follow an ongoing enforcement proceeding in the US District Court for the District of Delaware, with a jury trial scheduled for September 2025.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK